Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Diseases 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 11Cytarabine 8Methotrexate 6Etoposide 6Dexamethasone 6Vincristine 5Radiotherapy 5Doxorubicin 5Daunorubicin 5pegaspargase 4Trimethoprim, Sulfamethoxazole Drug Combination 4Mercaptopurine 4Idarubicin 4gamma-Globulins 3fludarabine phosphate 3Whole-Body Irradiation 3Prednisone 3N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Methylprednisolone 3Gemtuzumab 3Filgrastim 3Clofarabine 3Ciprofloxacin 3Busulfan 3etoposide phosphate 2blinatumomab 2Thioguanine 2Melphalan 2Karyotyping 2Injections, Spinal 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Leukemia × cedazuridine × Clear all
NCT04256317 2026-04-30

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Taiho Oncology, Inc.

Phase 2/3 Recruiting
316 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡